Total Payments
$21,342
2024 Payments
$2,940
Companies
68
Transactions
1,206
Medicare Patients
2,231
Medicare Billing
$253,070
Payment Breakdown by Category
Food & Beverage$19,975 (93.6%)
Other$1,029 (4.8%)
Consulting$200.00 (0.9%)
Education$137.45 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $19,975 | 1,182 | 93.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $830.00 | 4 | 3.9% |
| Consulting Fee | $200.00 | 2 | 0.9% |
| Long term medical supply or device loan | $199.40 | 2 | 0.9% |
| Education | $137.45 | 16 | 0.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,213 | 111 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $1,958 | 139 | $0 (2024) |
| Amgen Inc. | $1,440 | 87 | $0 (2023) |
| Celgene Corporation | $1,326 | 92 | $0 (2024) |
| Genentech USA, Inc. | $1,283 | 85 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,190 | 66 | $0 (2024) |
| GENZYME CORPORATION | $944.20 | 23 | $0 (2024) |
| Merck Sharp & Dohme LLC | $918.22 | 64 | $0 (2024) |
| Exelixis Inc. | $729.98 | 41 | $0 (2024) |
| Seagen Inc. | $722.92 | 42 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,940 | 142 | Novartis Pharmaceuticals Corporation ($528.13) |
| 2023 | $3,038 | 150 | E.R. Squibb & Sons, L.L.C. ($365.44) |
| 2022 | $3,003 | 150 | Amgen Inc. ($280.10) |
| 2021 | $2,809 | 138 | GENZYME CORPORATION ($439.57) |
| 2020 | $1,614 | 97 | Amgen Inc. ($189.78) |
| 2019 | $2,653 | 170 | Novartis Pharmaceuticals Corporation ($293.82) |
| 2018 | $2,789 | 187 | Novartis Pharmaceuticals Corporation ($406.73) |
| 2017 | $2,497 | 172 | E.R. Squibb & Sons, L.L.C. ($398.33) |
All Payment Transactions
1,206 individual payment records from CMS Open Payments — Page 1 of 49
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $18.18 | General |
| 12/17/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $14.69 | General |
| Category: Hematology | ||||||
| 12/17/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $4.33 | General |
| Category: Hematology | ||||||
| 12/16/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $23.15 | General |
| Category: Oncology | ||||||
| 12/12/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | Cash or cash equivalent | $16.66 | General |
| Category: Oncology / Rare Diseases | ||||||
| 12/10/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 12/09/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $27.40 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 12/05/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $23.57 | General |
| Category: ONCOLOGY | ||||||
| 12/04/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $13.87 | General |
| Category: Oncology | ||||||
| 12/03/2024 | INTUITIVE SURGICAL, INC. | Da Vinci Surgical System (Device) | Food and Beverage | In-kind items and services | $113.64 | General |
| Category: SURGERY | ||||||
| 12/03/2024 | INTUITIVE SURGICAL, INC. | Da Vinci Surgical System (Device) | Food and Beverage | In-kind items and services | $51.90 | General |
| Category: SURGERY | ||||||
| 12/03/2024 | ARRAY BIOPHARMA INC | LORBRENA (Drug), BRAFTOVI, MEKTOVI | Food and Beverage | In-kind items and services | $18.03 | General |
| Category: ONCOLOGY | ||||||
| 11/26/2024 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $15.56 | General |
| Category: Hematology | ||||||
| 11/26/2024 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $0.86 | General |
| Category: Hematology | ||||||
| 11/25/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $22.86 | General |
| Category: Immunology | ||||||
| 11/22/2024 | Genentech USA, Inc. | Venclexta (Biological) | Food and Beverage | In-kind items and services | $18.56 | General |
| Category: BioOncology | ||||||
| 11/21/2024 | PFIZER INC. | INLYTA (Drug), XTANDI, TUKYSA | Food and Beverage | In-kind items and services | $18.70 | General |
| Category: ONCOLOGY | ||||||
| 11/19/2024 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $14.25 | General |
| Category: Oncology | ||||||
| 11/15/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $23.14 | General |
| 11/14/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 11/07/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $21.81 | General |
| Category: Oncology | ||||||
| 11/05/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $25.51 | General |
| Category: Oncology | ||||||
| 11/05/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $14.15 | General |
| Category: Oncology | ||||||
| 11/04/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $15.05 | General |
| Category: Oncology | ||||||
| 11/01/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $20.71 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 494 | 858 | $237,180 | $54,799 |
| 2022 | 9 | 550 | 897 | $180,625 | $59,433 |
| 2021 | 8 | 546 | 969 | $204,935 | $67,983 |
| 2020 | 9 | 641 | 1,174 | $251,430 | $70,854 |
Total Patients
2,231
Total Services
3,898
Medicare Billing
$253,070
Procedure Codes
34
All Medicare Procedures & Services
34 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 143 | 373 | $112,775 | $25,817 | 22.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 201 | 305 | $65,175 | $13,193 | 20.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 47 | 47 | $24,315 | $5,971 | 24.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 21 | 29 | $6,960 | $2,604 | 37.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 17 | 22 | $9,350 | $2,372 | 25.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 25 | 25 | $9,875 | $2,231 | 22.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 21 | 33 | $5,610 | $1,969 | 35.1% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 19 | 24 | $3,120 | $640.32 | 20.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 166 | 369 | $71,955 | $25,087 | 34.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 209 | 300 | $40,500 | $13,165 | 32.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 64 | 64 | $25,280 | $8,615 | 34.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 16 | 50 | $15,250 | $3,920 | 25.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 24 | 28 | $7,420 | $2,690 | 36.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 24 | 37 | $8,140 | $2,004 | 24.6% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 12 | 12 | $4,620 | $1,807 | 39.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 20 | 20 | $6,100 | $1,677 | 27.5% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 15 | 17 | $1,360 | $468.61 | 34.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 172 | 414 | $80,730 | $28,886 | 35.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 185 | 257 | $34,695 | $12,078 | 34.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 35 | 99 | $30,195 | $7,854 | 26.0% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 56 | 56 | $22,120 | $7,783 | 35.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 40 | 84 | $18,480 | $4,591 | 24.8% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 29 | 29 | $8,845 | $2,936 | 33.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 16 | 16 | $6,160 | $2,346 | 38.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 13 | 14 | $3,710 | $1,510 | 40.7% |
About Dr. Matthew Mccarty, MD
Dr. Matthew Mccarty, MD is a Hematology & Oncology healthcare provider based in Maryville, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/23/2006. The National Provider Identifier (NPI) number assigned to this provider is 1184694333.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Matthew Mccarty, MD has received a total of $21,342 in payments from pharmaceutical and medical device companies, with $2,940 received in 2024. These payments were reported across 1,206 transactions from 68 companies. The most common payment nature is "Food and Beverage" ($19,975).
As a Medicare-enrolled provider, Mccarty has provided services to 2,231 Medicare beneficiaries, totaling 3,898 services with total Medicare billing of $253,070. Data is available for 4 years (2020–2023), covering 34 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Maryville, TN
- Active Since 01/23/2006
- Last Updated 06/29/2010
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1184694333
Products in Payments
- OPDIVO (Biological) $1,454
- KEYTRUDA (Biological) $922.46
- ADCETRIS (Biological) $726.77
- KISQALI (Drug) $682.11
- JAKAFI (Drug) $605.01
- REBLOZYL (Biological) $518.55
- CABLIVI (Biological) $400.00
- DARZALEX (Biological) $397.68
- LIBTAYO (Biological) $368.04
- CABOMETYX (Drug) $361.61
- TAGRISSO (Drug) $358.03
- LUMAKRAS (Drug) $317.63
- Nplate (Biological) $311.74
- Lenvima (Drug) $297.80
- CALQUENCE (Drug) $297.21
- TUKYSA (Drug) $287.54
- Cabometyx (Drug) $278.48
- Avastin (Biological) $275.60
- Pomalyst (Drug) $269.08
- PROMACTA (Drug) $250.13
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.